Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Deciphera Pharmaceuticals $135.1 million common stock offering
The common stock is listed on the Nasdaq Global Select Market
Tricida chapter 11 liquidation
We are advising noteholders in connection with Tricida’s chapter 11 proceedings
Sun Pharmaceutical acquisition of Concert Pharmaceuticals
We advised Sun Pharmaceutical on the transaction
Jinxin Fertility Group HK$1.17 billion top-up placement of shares
The shares are listed on the Hong Kong Stock Exchange
Novavax $175.25 million convertible senior notes offering
The 5% convertible notes are due 2027
Terns Pharmaceuticals $86 million stock offering
The stock is listed on the Nasdaq Global Select Market
Coherus BioSciences $150 million at-the-market offering
The stock is listed on the Nasdaq Global Market
Priveterra Acquisition initial business combination with AEON Biopharma
We are advising Priveterra on the transaction
Illumina $1 billion notes offering
The investment-grade notes are due 2027
Prometheus Biosciences $500 million follow-on offering
The shares are listed on the Nasdaq Global Select Market